by John Conrad | Jun 10, 2024 | NewsBrief
In a significant development for patients with vanishing white matter (VWM) disease, AbbVie and Alphabet’s Calico announced on Friday that their investigational eIF2B activator, fosigotifator, has been selected to participate in the FDA’s new Support for...
